Press Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle 
08/11/17Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference
BURLINGAME, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City, New York. The presentation is scheduled for Wednesday, August 16, at 1:20pm Eastern Time. A webcast of the presentation will be available live and for 30 d... 
Printer Friendly Version
08/03/17Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the second quarter ended June 30, 2017, and provided a business update. “We continue to make significant progress in advancing the clinical development of our lead product candidate, CPI-444, and other product candidates in our imm... 
Printer Friendly Version
07/06/17Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology
BURLINGAME, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will host an R&D Day on Tuesday, July 11, 2017, in New York City and provide a live webcast starting at 9:00 a.m. ET.  The event will focus on the adenosine pathway in immuno-oncology and its potential to address the limitations of existing agen... 
Printer Friendly Version
06/05/17Corvus Pharmaceuticals Announces Interim Results Demonstrating Anti-Tumor Activity of CPI-444 in Renal and Lung Cancer Patients Resistant or Refractory to Prior PD-(L)1 Treatment
-- Clinical Data from Company’s Ongoing Phase 1/1b Study in Expansion Cohorts Presented in Oral Presentation at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting – Key Study Results in RCC Patients ... 
Printer Friendly Version
05/15/17Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 in Renal and Lung Cancer at 2017 ASCO Annual Meeting
BURLINGAME, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present an oral abstract presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, Illinois. The abstract for the presentation will be available on the ASCO website on May 17 at 5:00 ... 
Printer Friendly Version
05/09/17Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program
BURLINGAME, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company, announced today that it has licensed global rights to an undisclosed novel immuno-oncology program, which includes a lead product candidate, from Monash University. Corvus Pharmaceuticals, which focuses on the development and commercialization of novel immuno-oncology therapies, plans to develop any product candidates that result from the collaboration... 
Printer Friendly Version
05/04/17Corvus Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
BURLINGAME, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the first quarter ended March 31, 2017, and provided a business update. “We are continuing to make significant progress in our Phase 1/1b trial, which is designed to rapidly identify the diseases where our lead product candidate, CP... 
Printer Friendly Version
05/02/17Corvus Pharmaceuticals Expands CPI-444 Clinical Collaboration with Genentech
CPI-444 in Combination with Atezolizumab Will Advance into Phase 1b/2 Study in Patients with Non-Small Cell Lung Cancer who are Resistant/Refractory to Prior Anti-PD(L)-1 Treatment as Part of MORPHEUS, Genentech’s Novel Cancer Immunotherapy Development Platform BURLINGAME, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today ann... 
Printer Friendly Version
04/04/17Corvus Pharmaceuticals Announces Interim Results from Ongoing Phase 1/1b Study Demonstrating Safety and Clinical Activity of Lead Checkpoint Inhibitor CPI-444 in Patients with Advanced Cancers
– Clinical Data Presented in Oral Plenary Session at American Association for Cancer Research (AACR) Annual Meeting 2017 – – Data Supports Expansion of Three Additional Cohorts in Non-small Cell Lung Cancer Treated with Single Agent CPI-444, Renal Cell Cancer and Non-small Cell Lung Cancer Treated with CPI-444 in Combination with Atezolizumab –  – Additional CPI-444 Data and Preclinical Data on Corvus’ Anti-CD73 Monoclonal Antibody to be Presented in Poster Sessions – BURLINGAME, Calif., A... 
Printer Friendly Version
03/20/17Corvus Pharmaceuticals to Present Data That Advances the Understanding of the Adenosine Pathway in Immuno-Oncology, including New Clinical Data on CPI-444 at AACR 2017
Company Has Six Presentations at AACR Highlighting Clinical and Preclinical Data BURLINGAME, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present interim data from its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab) in an oral ple... 
Printer Friendly Version
03/13/17Corvus Pharmaceuticals to Reschedule R&D Day Due to Severe Winter Storm in the New York Tri-State Area
BURLINGAME, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, announced that the company will postpone its R&D Day scheduled for March 14, 2017 due to an anticipated severe winter snowstorm forecasted to hit the New York tri-state area and its impact on the travel schedule and participation of its principal presenters. The comp... 
Printer Friendly Version
03/10/17Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
BURLINGAME, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the fourth quarter and year ended December 31, 2016, and provided a business update. “In 2016, Corvus made the successful transition to becoming a public company, initiated clinical investigation of our lead program, CPI-444, and ... 
Printer Friendly Version
03/09/17Corvus Pharmaceuticals to Host R&D Day Highlighting the Role of the Adenosine Pathway in Immuno-Oncology
Company to Provide Opportunity to Participate in the Event via Live and Archived Webcast BURLINGAME, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will host and provide a live webcast for its R&D Day, starting at 9:00 AM ET on March 14, 2017 in New York City.   The event will highlight the... 
Printer Friendly Version
02/27/17Corvus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference 2017
BURLINGAME, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the Cowen and Company 37th Annual Health Care Conference 2017 in Boston, Massachusetts. The presentation is scheduled for Monday, March 6, at 4:00 p.m. Eastern Time. A webcast of the presentation will be available live a... 
Printer Friendly Version
01/10/17Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444
-- Cohort Reached Protocol-Predefined Criteria for Expansion  Based on Responses to Single-Agent Treatment -- BURLINGAME, Calif., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the protocol-predefined criteria for expansion has been reached for the cohort of patients with renal cell carcinoma treated with single-ag... 
Printer Friendly Version
01/04/17Corvus Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017
BURLINGAME, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 35th Annual J.P. Morgan Healthcare Conference 2017 in San Francisco. The presentation is scheduled for Thursday, January 12, at 8:00 a.m. Pacific Time. A webcast of the presentation will be available live and for 7 d... 
Printer Friendly Version
01/03/17Corvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of Directors
BURLINGAME, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS) today announced the appointment of Ian T. Clark, former chief executive officer and head of North American Commercial Operations at Genentech, Inc., to its Board of Directors. "Ian is an ideal addition to our Board because of his considerable expertise in guiding the commercialization of novel therapeutics, particularly in oncology,” said Richard A. Miller, an oncologist and co-founder, presiden... 
Printer Friendly Version
11/11/16Corvus Pharmaceuticals Announces Preliminary Phase 1/1b Clinical Data with Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety and Evidence of Anti-Tumor Activity as a Single Agent in Patients with Advanced Refractory Cancers
-- Biomarker Data Also Presented Indicating Evidence of Immune Activation-- --Data Presented at SITC’s 31st Annual Meeting-- BURLINGAME, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced preliminary clinical safety and efficacy data from the dose-selection phase of its ongoing Phase 1/1b study of CPI-444 as a sin... 
Printer Friendly Version
11/03/16Corvus Pharmaceuticals Announces Third Quarter Financial Results and Provides Business Update
BURLINGAME, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the third quarter and nine months ended September 30, 2016 and provided a business update. “We continue to make good progress on the development of our lead product candidate, CPI-444,” said Richard A. Miller, M.D., co-founder, pre... 
Printer Friendly Version
11/02/16Corvus Pharmaceuticals to Present at SITC’s 31st Annual Meeting
BURLINGAME, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it will present preliminary clinical and biomarker data from its from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech’s TECENTRIQ® (atezolizumab), at the Society for Immunotherapy of Cancer’s (SITC) 31st Annual ... 
Printer Friendly Version
11/01/16Corvus Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference
BURLINGAME, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that management will present at the Credit Suisse 25th Annual Healthcare Conference on Tuesday, November 8 at 10:30 a.m. MT in Scottsdale, Arizona. A webcast of the presentation will be available live and for 30 days following the event. The webcast may... 
Printer Friendly Version
10/10/16Corvus Pharmaceuticals Announces Biomarker Findings from Phase 1/1b Study of Lead Oral Checkpoint Inhibitor CPI-444 Presented at ESMO 2016 Congress
Company Completes Enrollment in Dose-Selection Part of Clinical Trial BURLINGAME, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced biomarker findings from its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s TECENTRIQ® (atezolizumab),‎ a fully humanized monoclonal antibody t... 
Printer Friendly Version
10/04/16Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at ESMO 2016 Congress
BURLINGAME, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present preclinical data and preliminary biomarker data from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech’s TECENTRIQ™ (atezolizumab), in poster presentation sessions at the European Society for ... 
Printer Friendly Version
09/25/16Corvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 Presented at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
--Preclinical Studies Demonstrate Activity of CPI-444 Both Alone and in Combination with Anti-PD-1 and Anti-PD-L1 Antibodies--  --Preliminary Phase 1/1b Clinical Biomarker Data Show Complete Blockade of Peripheral Blood Lymphocyte A2A Receptors in Dose-Dependent Manner and Induction of Activated T-Cells-- BURLINGAME, Calif., Sept. 25, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercializatio... 
Printer Friendly Version
09/19/16Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
BURLINGAME, Calif., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present preclinical data, and preliminary biomarker data from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech’s TECENTRIQ™ (atezolizumab)‎, in both oral and poster presentations at the Second CRI-C... 
Printer Friendly Version
08/04/16Corvus Pharmaceuticals Announces Second Quarter Financial Results and Provides Business Update
BURLINGAME, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), today announced financial results for the second quarter and six months ended June 30, 2016 and provided a business update. “We are making good progress with our product candidates,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “Enrollment in the dose selection stage of our Phase 1/1b trial with our lead product candidate, CPI-444, is continuing on ... 
Printer Friendly Version
07/06/16Corvus Pharmaceuticals to Present at Cantor Fitzgerald’s Second Annual Healthcare Conference on July 12
BURLINGAME, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced management will present at the Cantor Fitzgerald Second Annual Healthcare Conference on July 12 at 11:45 a.m. EDT at Le Parker Meridien Hotel, New York. A webcast of the presentation will be available live and for 30 days following the event. The webcas... 
Printer Friendly Version
06/29/16Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
BURLINGAME, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it has named former Roche/Genentech Vice President, Global Head of Roche Oncology Business Development, Jason, V. Coloma, Ph.D., to the newly created post of Senior Vice President and Chief Business Officer. ... 
Printer Friendly Version
06/17/16Corvus Pharmaceuticals’ Ian McCaffery, PhD to Present at Rational Combinations 360° June 23-24, New York
BURLINGAME, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced Corvus’s Dr. Ian McCaffery will present at the inaugural Rational Combinations 360° event at the Park Lane Hotel, New York, June 23 – 24.  The conference will encompass the most up-to-date developments from the business, clinical and scientific perspect... 
Printer Friendly Version
05/05/16Corvus Pharmaceuticals Announces First Quarter 2016 Financial Results
BURLINGAME, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced financial results for the three months ended March 31, 2016. "Since commencing operations in November 2014, we’ve made substantial progress and today, we have four product candidates in our pipeline focused on immuno-oncology therapies,” said Richard A. ... 
Printer Friendly Version
04/19/16Corvus Pharmaceuticals Announces Results of Preclinical Studies Demonstrating Enhanced Immune Responses and Anti-Tumor Activity with CPI-444, an Investigational Immuno-Oncology Therapy
Data from Studies of Novel Checkpoint Inhibitor Presented in Oral and Poster Presentation Sessions at American Association for Cancer Research Annual Meeting 2016 BURLINGAME, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced results of three preclinical studies of CPI-444, the Company’s lead oral checkpoint inhibit... 
Printer Friendly Version
04/05/16Corvus Pharmaceuticals to Present at AACR Annual Meeting April 16 – 20 in New Orleans
Poster Presentations Scheduled for April 17 & 18; Oral Presentation on April 19 BURLINGAME, Calif. , April 05, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced oral and poster presentations of key preclinical data relating to certain of its drug development programs at the American Association of Cancer R... 
Printer Friendly Version
03/22/16Corvus Announces Pricing of Initial Public Offering
BURLINGAME, Calif., March 22, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced the pricing of its initial public offering of 4,700,000 shares of its common stock at an initial public offering price of $15.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 705,000 shares of common stock a... 
Printer Friendly Version
10/26/15Corvus Pharmaceuticals Enters Clinical Trial Collaboration Agreement
Multicenter Phase 1/1b Trial to Assess Safety and Preliminary Efficacy of Corvus’ Lead Oral Checkpoint Inhibitor and Genentech’s Atezolizumab to Treat Patients with Cancer Burlingame, CA, October 26, 2015 – Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer therapies by harnessing the immune system, announced today that it entered into a clinical trial collaboration agreement with Genentech, a member ... 
Printer Friendly Version
09/29/15Corvus Pharmaceuticals Completes $75 Million Series B Financing
Funds will Advance Company’s Immuno-Oncology Small Molecule and Antibody Programs Burlingame, CA, September 29, 2015 – Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development of novel agents targeting the immune system to treat patients with cancer, today announced that it closed a $75 million Series B financing. The transaction was led by Rock Springs Capital Management and included other leading healthcare investors such as Fid... 
Printer Friendly Version
07/01/15Former Pharmacyclics CEO Raises $33.5M Series A for Corvus Pharmaceuticals
Venture firms are betting that the founding chief executive of Pharmacyclics Inc., acquired by AbbVie Inc. for $21 billion, will develop another blockbuster cancer therapy through newly formed Corvus Pharmaceuticals Inc. Richard A. Miller launched Corvus last year and raised a $33.5 million Series A round in December led by OrbiMed Advisors. With Pharmacyclics, formed in 1991, he initiated a program to develop Imbruvica, a blood cancer therapy that w... 
Printer Friendly Version